RTP Mobile Logo
Oncology Grand Rounds Series: Multiple Myeloma (Webinar Audio Proceedings) — an NCPD-Accredited Program for Nurses
Released June 2021

Proceedings from the seventh in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Shaji K Kumar, Sagar Lonial and Paul G Richardson on cases from the practices of Ms Charise Gleason, Ms Patricia Mangan and Dr Tiffany A Richards. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with multiple myeloma.

    LEARNING OBJECTIVES

    • Customize induction and subsequent maintenance therapeutic approaches for patients with MM eligible or ineligible for stem cell transplant, considering recently presented clinical trial findings and patient- and disease-related factors, including cytogenetic profile.
    • Discuss new and existing research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and evaluate how this strategy should be integrated into the clinical management of this disease.
    • Evaluate available and emerging efficacy and safety data with CAR (chimeric antigen receptor) T-cell therapies directed at BCMA (B-cell maturation antigen), and identify patients with relapsed/refractory MM for whom this approach may be appropriate.
    • Develop an understanding of the mechanisms of action of the FDA-approved agents melphalan flufenamide (melflufen), belantamab mafodotin and idecabtagene vicleucel in patients with relapsed/refractory MM.
    • Educate patients about the side effects associated with approved therapies commonly used in the management of MM, and provide preventive strategies to reduce or ameliorate these toxicities.
    • Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel and investigational approaches for MM, and develop strategies to effectively counsel patients about the potential benefits of participation in research protocols.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    NCPD credit is no longer available for this issue

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSMM2021/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: This NCPD activity consists of an audio component.
    NCPD credit is no longer available for this issue

    Video Program: This NCPD activity consists of a video component.
    NCPD credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Shaji K Kumar, MD
    Mark and Judy Mullins Professor of Hematological Malignancies
    Consultant, Division of Hematology
    Professor of Medicine
    Mayo Clinic
    Rochester, Minnesota

    Consulting/Advisory Board: Antengene, BeiGene Ltd, Oncopeptides; Consulting/Advisory Board (no personal payments): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Takeda Oncology; Research Funding for Clinical Trials to the Institution: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio.

    Sagar Lonial, MD
    Chair and Professor
    Department of Hematology and Medical Oncology
    Anne and Bernard Gray Family Chair in Cancer
    Chief Medical Officer
    Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

    Paul G Richardson, MD
    Clinical Program Leader and Director of Clinical Research
    Jerome Lipper Multiple Myeloma Center
    Dana-Farber Cancer Institute
    RJ Corman Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Secura Bio, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology.

    Oncology Nurse Practitioners

    Charise Gleason, MSN, NP-C, AOCNP
    Advanced Practice Provider Chief
    Winship Cancer Institute of Emory University
    Adjunct Faculty, Nell Hodgson Woodruff School of Nursing
    Atlanta, Georgia

    No relevant conflicts of interest to disclose.

    Patricia Mangan, RN, MSN, CRNP, APN, BC
    Nurse Lead, Hematologic Malignancies and Stem Cell Transplant Programs
    Abramson Cancer Center
    University of Pennsylvania
    Philadelphia, Pennsylvania

    Consulting Agreements: GlaxoSmithKline, Merck; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology.

    Tiffany A Richards, PhD, ANP-BC, AOCNP
    Nurse Practitioner
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Celgene Corporation, GlaxoSmithKline, Sanofi Genzyme, Takeda Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from GlaxoSmithKline and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Release date: June 2021
    Expiration date: June 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):